Results 11 to 20 of about 949,070 (290)

Use of Proteasome Inhibitors

Current Protocols in Immunology, 2015
AbstractProteasome inhibitors are indispensable research tools in immunology and cell biology. With numerous proteasome inhibitors available commercially, choosing the appropriate compound for a biological experiment may be challenging, especially for a novice. This unit provides an overview of the proteasome inhibitors commonly used in research.
Downey, S.L., Florea, B.I., Overkleeft, H.S., Kisselev, A.F.   +3 more
openaire   +4 more sources

The capture proteasome assay (CAPA) to evaluate subtype-specific proteasome inhibitors [PDF]

Data in Brief, 2015
We recently developed a new assay to measure proteasome activity in vitro (CAPA for capture proteasome assay) [1], based on proteasome capture on an antibody-coated plate.
Nathalie Vigneron, Joanna Abi Habib, Benoît J. Van den Eynde   +2 more
doaj   +2 more sources

Hydroxyureas as Noncovalent Proteasome Inhibitors

Angewandte Chemie International Edition, 2011
Inhibitors with a new mechanism of action are needed for 20S proteasome (CP) inhibition owing to the ineffectiveness of current market drugs against some types of solid tumors. A novel class of nonpeptidic CP inhibitors has been developed, which display reversible and noncovalent binding.
Gallastegui, Nerea, Beck, Philipp, Arciniega, Marcelino, Huber, Robert, Hillebrand, Stefan, Groll, Michael   +5 more
openaire   +6 more sources

Homopiperazine derivatives as a novel class of proteasome inhibitors with a unique mode of proteasome binding. [PDF]

PLoS ONE, 2013
The proteasome is a proteolytic machinery that executes the degradation of polyubiquitinated proteins to maintain cellular homeostasis. Proteasome inhibition is a unique and effective way to kill cancer cells because they are sensitive to proteotoxic ...
Jiro Kikuchi, Naoya Shibayama, Satoshi Yamada, Taeko Wada, Masaharu Nobuyoshi, Tohru Izumi, Miyuki Akutsu, Yasuhiko Kano, Kanako Sugiyama, Mio Ohki, Sam-Yong Park, Yusuke Furukawa   +11 more
doaj   +2 more sources

Computational Approaches for the Discovery of Human Proteasome Inhibitors: An Overview

Molecules, 2016
Proteasome emerged as an important target in recent pharmacological research due to its pivotal role in degrading proteins in the cytoplasm and nucleus of eukaryotic cells, regulating a wide variety of cellular pathways, including cell growth and ...
Romina A. Guedes, Patrícia Serra, Jorge A. R. Salvador, Rita C. Guedes   +3 more
doaj   +2 more sources

Joining the Army of Proteasome Inhibitors

Chemistry & Biology, 2008
An article in this issue of Chemistry & Biology (Hines et al., 2008) and a recent study in Nature (Groll et al., 2008) establish three natural products as novel proteasome inhibitors. These inhibitors, discovered in an unusual way, reveal a different mechanism of proteasome inhibition and suggest new therapeutic application of its inhibitors.
Kisselev, Alexei F.
openaire   +3 more sources

Proteasome Inhibitors in Waldenström Macroglobulinemia

Hematology/Oncology Clinics of North America, 2018
Waldenström macroglobulinemia (WM) remains an incurable B-cell lymphoproliferative disorder, yet therapy is only considered for patients with symptomatic disease. Primary therapy options for WM include combinations based on anti-CD20 monoclonal antibodies, mainly rituximab. However, proteasome inhibitors have become an important part of WM therapy both
Kastritis, Efstathios, Dimopoulos, Meletios A   +1 more
core   +7 more sources

New proteasome inhibitors in the treatment of multiple myeloma

Hematology, Transfusion and Cell Therapy, 2019
The treatment of patients with relapsed and/or refractory multiple myeloma has improved considerably in the last 15 years, after the introduction of proteasome inhibitors and immunomodulatory drugs.
Vania Tietsche de Moraes Hungria, Edvan de Queiroz Crusoé, Rosane Isabel Bittencourt, Angelo Maiolino, Roberto José Pessoa Magalhães, Jairo do Nascimento Sobrinho, Jorge Vaz Pinto, Ricardo Coutinho Fortes, Eloisa de Sá Moreira, Paula Yurie Tanaka   +9 more
doaj   +2 more sources

Cardiovascular toxicity of proteasome inhibitors in multiple myeloma therapy

, 2022
The treatment for multiple myeloma has advanced significantly over the past few decades. Proteasome inhibitors have become the cornerstone of the treatment of multiple myeloma.
Huang, Shan, Tse, Gary, Xie, Bingxin, Liu, Tong, Zhang, Nan, Zheng, Yi, Liu, Zhiqiang   +6 more
core   +2 more sources

Proteasome inhibitors

Biochemical Pharmacology, 2015
Proteasome inhibitors have a 20 year history in cancer therapy. The first proteasome inhibitor, bortezomib (Velcade, PS-341), a break-through multiple myeloma treatment, moved rapidly through development from bench in 1994 to first approval in 2003. Bortezomib is a reversible boronic acid inhibitor of the chymotrypsin-like activity of the proteasome ...
Teicher, Beverly A., Tomaszewski, Joseph E.   +1 more
openaire   +4 more sources